DUPONT MERCK NEW PRESIDENT AND CEO LANDGRAF
Executive Summary
DUPONT MERCK NEW PRESIDENT AND CEO LANDGRAF is a 13-year DuPont veteran who will succeed Joseph Mollica, PhD, Dec. 1 when Mollica retires, the company announced Nov. 11. Kurt Landgraf, 47, has been in charge of sales, marketing and manufacturing for both the domestic and international sectors of DuPont Merck since the start-up of the joint venture in January 1991, when he was named exec VP. DuPont Merck has not appointed anyone to succeed Landgraf. The selection of Landgraf to succeed Mollica continues the dominance of former DuPont execs as the topsiders of the three- year-old joint venture ("The Pink Sheet" Feb. 11, 1991, T&G-7). Prior to the merger, Landgraf was director of the pharmaceuticals and imaging agents divisions and medical products department at DuPont; he also had a stint in DuPont's corporate plans department as a planning manager and was the pharmaceutical marketing director for Europe, the Middle East and Africa. Before joining DuPont in 1980, Landgraf worked at Upjohn and Johnson & Johnson. Mollica was also a former DuPont exec. The departure of Mollica, 53, is being characterized by DuPont Merck as a desire on his part to find an opportunity similar to the one he landed when the joint-venture was formed in mid-1990: he is hoping to "capitalize on his talents and abilities in creating and turning around organizations," the company said. During Mollica's tenure, sales doubled to over $1 bil. and DuPont Merck expanded its European presence, including the opening of subsidiaries in Italy and Spain; DuPont Merck markets its products in 80 countries.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth